Government authorities have denied reports of a widespread insulin shortage in Pakistan, saying that alternatives remain available, after patients with Type 1 diabetes raised concerns online over the unavailability of Apidra, a brand they rely on to manage their disease.

The health ministry and the Drug Regulatory Authority of Pakistan (DRAP) said that insulin glulisine, sold under the brand name Apidra by Sanofi, was unavailable because of international supply constraints.